ARYx Therapeutics Inc (ARYX)

[bbking2003]

Two drugs with issues - possible Aryx opportunity,Merck and Sanofi recently announced problems with two drugs and both with possible positive implications for the Aryx portfolio.
Merck: Merck shares fell after the company said it discontinued a clinical trial of an anti-clotting drug that was a prominent part of the company’s pipeline and was likely to be submitted for marketing approval this year.The company also said it reduced the size of another trial of the same drug, vorapaxar.
Sanofi:Associated Press - Jan. 14, 2011
WASHINGTON -- Federal health officials are warning doctors and patients that a recently launched heart drug from Sanofi-Aventis SA is linked to liver damage in a handful of U.S. patients.
The Food and Drug Administration said it has received several reports of liver damage with Multaq tablets, including two cases in which patients had had to have their livers removed.
The FDA approved Multaq in 2009 to treat atrial flutter and atrial fibrillation, which are irregular heart rhythms that can reduce blood flow and lead to stroke.